GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Natco Pharma Ltd

Natco Pharma Board approves demerger of agrochemicals business, Nigeria subsidiary

BOARD ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 24 Mar 2026, 05:30 PM IST  ·  BSE ID: 51585785-f38d-4316-874c-8cd20dc2c363
View Original BSE Filing (PDF)
💡
In Simple Terms
Natco Pharma is splitting its crop chemicals business into a separate company that shareholders will own alongside the parent.
🤖 AI Summary
  • Board approved demerger scheme to separate agrochemicals business into Natco Crop Health Sciences Limited
  • Share entitlement ratio: 1 new share of INR 2 for each 1 parent share held
  • Appointed date: October 1, 2026; requires shareholder, creditor, and NCLT approval
  • Incorporate Nigeria subsidiary with up to USD 100,000 investment; liquidate Australian subsidiary
🔢 Key Numbers — exact figures from BSE filing, not rounded
Share entitlement ratio
1 equity share of INR 2 each in new company for every 1 share held in Natco Pharma
Appointed date
October 1, 2026
Nigeria subsidiary investment
Up to USD 100,000
🏢 How This Affects the Company
📈
Business Impact
Demerger separates agrochemicals business into independent listed entity, allowing focused strategy and distinct market positioning for each division. Crop health business operates as standalone under Natco Crop Health Sciences Limited.
💰
Financial Impact
Balance sheet will separate agrochemicals assets and liabilities into the new entity. Shareholders retain equity stake in both companies with 1:1 share issuance ratio at INR 2 per share.
⚙️
Operational Impact
Agrochemicals operations transfer to Natco Crop Health Sciences as going concern. Parent company retains pharmaceutical business. Australia subsidiary liquidation removes non-core operations.
⚠️
Risk Impact
Demerger subject to NCLT, shareholder, and creditor approval — execution risk until approvals obtained. Market liquidity in new share post-listing uncertain. Operational separation requires clear asset and liability demarcation.
👥 What This Means For Shareholders
✅
Action Required
Await shareholder meeting notification and voting on demerger scheme; ensure demat shares held before record date for new share entitlement.
👤
Who Is Affected
All existing Natco Pharma shareholders will receive 1 equity share of INR 2 in Natco Crop Health Sciences for each share held, creating dual shareholding post-demerger.
🔍
Management Signal
Deliberate strategic separation to unlock value in agrochemicals business and enable independent growth trajectories for pharma and crop health divisions.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
NCLT petition filing and approval status — demerger cannot proceed without tribunal sanction
Extraordinary General Meeting notice for shareholder approval of demerger scheme and voting results
Stock exchange no-objection letters under Regulation 37 LODR and listing application timeline
MEDIUM RISK Demerger contingent on multiple regulatory approvals (NCLT, shareholder, creditor) with no guaranteed timeline. Market reception of new listed entity uncertain.
💡 Investor Takeaway
Board approved demerger creating Natco Crop Health Sciences Limited with 1:1 share ratio at INR 2 per share. Appointed date October 1, 2026. Requires NCLT, shareholder, and creditor approval. New entity will list separately on stock exchanges.
⚖️ Strengths & Concerns

✅ Positives

  • Clear 1:1 share entitlement ratio provides transparent valuation mechanism for existing shareholders in both entities
  • Agrochemicals business transferred as going concern, preserving operational continuity and avoiding disruption

⚠️ Concerns

  • Demerger requires multiple approvals: shareholders, creditors, and NCLT — significant execution risk and extended timeline
  • New listed entity liquidity and investor appetite unproven; market reception of Natco Crop Health Sciences shares uncertain
⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.